In preclinical models, synthetic agonists of REV-ERBs, such as SR9009, exert anti-obesity effects by decreasing adiposity, enhancing insulin sensitivity, and inhibiting hepatic lipogenesis [181]. This evidence concerns the gene INS and obesity disorder.